Improve Access to Biomarker Testing 

With the Food and Drug Administration (FDA) approval of multiple treatments that slow the progression of Alzheimer’s in the early stages, early detection and diagnosis are even more critical to ensure individuals receive the most benefit at the earliest point possible. Biomarkers offer one of the most promising paths to improve dementia detection, diagnosis and treatment. Yet these critical tests remain out of reach for many as insurance coverage is failing to keep pace with innovations and advancements in treatments. The Alzheimer’s Association is urging state lawmakers to ensure insurance coverage of comprehensive biomarker testing. Without this legislation, dementia diagnoses may take up to two years, increasing the long-term costs to the individual, family and the state.